Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Triple-Combo Drug Shows Promise Against Antiviral-Resistant Swine Flu

29.10.2009
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

In laboratory testing, the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) and ribavirin showed a significant capacity to stop flu-virus growth, says Mark Prichard, Ph.D, who serves on the board of directors of the International Society for Antiviral Research. The combo drug works better in the test tube than currently recommended single or double antiviral therapies used to treat both seasonal and swine flu strains, he says.

Prichard presented his data in September at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco. The triple-combo testing is led by Adamas Pharmaceuticals, Inc. based in Emeryville, California.

"These findings suggest strongly that the triple combo is highly synergistic against virus replication, meaning it strikes multiple targets within H1N1 flu and other strains," Prichard says. "Only human testing will determine for sure, but this combo has the potential to be the antiviral therapy of choice for serious flu infection and to address Tamiflu resistance."

The synergy was seen in swine flu and seasonal flu strains, as well as H3N2 seasonal flu and the highly pathogenic H5N1 avian influenza strain, Prichard says. The dosing and timing of the combo mixture is protected information by Adamas. The company is starting human testing in the Southern Hemisphere, and has plans to begin human testing in North America once approval is obtained.

Because flu infection typically lasts for shorter periods of time than many other chronic infections, the three-pronged antiviral approach means the circulating strains of flu virus may not have time to develop resistance to the combo, Prichard says. "That's why this research is so timely, and why antiviral safety and testing data is crucial.

"If this triple combo could reduce the impact to families and the healthcare system that comes from serious flu cases, we would be thrilled."

The testing is partnership between UAB, Adamas, the United States Naval Health Research Center in San Diego, Utah State University in Logan, and the Amsterdam Medical Center in the Netherlands.

*Note: Prichard maintains a consulting agreement with Adamas Pharmaceuticals.

About Adamas Pharmaceuticals

Adamas is an emerging pharmaceutical company focused on developing small molecule, advantaged therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care.

About UAB

UAB is the state of Alabama's largest employer and an internationally renowned research university and academic health center whose professional schools and specialty patient care programs are consistently ranked as among the nation's top 50. The UAB Health System includes all of the University of Alabama at Birmingham's patient care activities, including UAB Hospital, the Callahan Eye Foundation Hospital and The Kirklin Clinic. Find more information at www.uab.edu and www.uabmedicine.org.

Media Contact:
Troy Goodman
205-934-8938
tdgoodman@uab.edu

Troy Goodman | EurekAlert!
Further information:
http://www.uabmedicine.org
http://www.uab.edu

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>